Independent Franchise Partners LLP Has $941.65 Million Stock Position in Solventum Corporation $SOLV

Independent Franchise Partners LLP raised its holdings in shares of Solventum Corporation (NYSE:SOLV) by 27.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,899,240 shares of the company’s stock after buying an additional 2,758,174 shares during the quarter. Solventum comprises about 6.2% of Independent Franchise Partners LLP’s holdings, making the stock its largest position. Independent Franchise Partners LLP owned 7.44% of Solventum worth $941,645,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. United Services Automobile Association bought a new stake in shares of Solventum during the 1st quarter valued at about $239,000. Woodline Partners LP increased its position in shares of Solventum by 40.7% in the first quarter. Woodline Partners LP now owns 11,677 shares of the company’s stock worth $888,000 after purchasing an additional 3,377 shares during the last quarter. Intech Investment Management LLC increased its position in shares of Solventum by 167.0% in the first quarter. Intech Investment Management LLC now owns 16,669 shares of the company’s stock worth $1,268,000 after purchasing an additional 10,425 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Solventum in the second quarter valued at approximately $343,000. Finally, Boston Partners raised its stake in Solventum by 9.2% in the second quarter. Boston Partners now owns 3,670,757 shares of the company’s stock valued at $278,363,000 after purchasing an additional 308,784 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on SOLV shares. BTIG Research reissued a “buy” rating and issued a $100.00 price target on shares of Solventum in a research note on Friday, February 27th. Wall Street Zen cut shares of Solventum from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Solventum in a report on Tuesday, January 27th. Mizuho set a $100.00 target price on Solventum and gave the company an “outperform” rating in a research note on Tuesday, January 20th. Finally, KeyCorp raised their price target on Solventum from $97.00 to $99.00 and gave the company an “overweight” rating in a research report on Friday, February 27th. Seven investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $93.70.

Solventum Stock Up 1.0%

Shares of NYSE SOLV opened at $66.76 on Friday. The stock has a market capitalization of $11.58 billion, a P/E ratio of 7.53, a PEG ratio of 1.08 and a beta of 0.40. Solventum Corporation has a one year low of $60.70 and a one year high of $88.20. The firm’s 50 day simple moving average is $76.40 and its two-hundred day simple moving average is $75.96. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.23 and a quick ratio of 0.89.

Solventum (NYSE:SOLV) last announced its quarterly earnings data on Thursday, February 26th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The firm had revenue of $2 billion during the quarter, compared to analyst estimates of $1.96 billion. During the same period in the previous year, the business posted $1.41 EPS. The business’s quarterly revenue was down 3.7% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. As a group, analysts expect that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Solventum declared that its board has approved a stock buyback program on Thursday, November 20th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 7.5% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling

In other Solventum news, Director Amy Mcbride Wendell purchased 1,475 shares of the stock in a transaction on Tuesday, March 10th. The stock was acquired at an average cost of $68.03 per share, with a total value of $100,344.25. Following the completion of the purchase, the director directly owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. This trade represents a 41.39% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.05% of the stock is currently owned by insiders.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.